Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Heron Therapeutics (HRTX) over the last 5 years, with Q3 2025 value amounting to $170.3 million.

  • Heron Therapeutics' Shares Outstanding (Diluted Average) rose 1146.24% to $170.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.3 million, marking a year-over-year increase of 1146.24%. This contributed to the annual value of $152.4 million for FY2024, which is 1036.23% up from last year.
  • Heron Therapeutics' Shares Outstanding (Diluted Average) amounted to $170.3 million in Q3 2025, which was up 1146.24% from $152.4 million recorded in Q4 2024.
  • Heron Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $170.3 million for Q3 2025, and its period low was $98471.0 during Q4 2021.
  • For the 5-year period, Heron Therapeutics' Shares Outstanding (Diluted Average) averaged around $120.4 million, with its median value being $119.5 million (2023).
  • The largest annual percentage gain for Heron Therapeutics' Shares Outstanding (Diluted Average) in the last 5 years was 11046656.27% (2022), contrasted with its biggest fall of 400.78% (2022).
  • Quarter analysis of 5 years shows Heron Therapeutics' Shares Outstanding (Diluted Average) stood at $98471.0 in 2021, then soared by 110466.56% to $108.9 million in 2022, then increased by 26.87% to $138.1 million in 2023, then increased by 10.36% to $152.4 million in 2024, then increased by 11.74% to $170.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $170.3 million in Q3 2025, compared to $152.4 million in Q4 2024 and $152.8 million in Q3 2024.